Participating Companies

De­vel­op­ing first-in-class se­lec­tive Axl ki­nase in­hibi­tors for liquid and solid can­cers, lead can­di­date is bem­cen­tinib (BG­B324) in four com­pany-spon­sored trials. [more in­for­ma­tion]

Cavro­toli­mod (AST-008) in Ph2 trials for pa­tients with Merkel Cell Car­ci­no­ma and Cu­ta­neous Squa­mous Cell Car­ci­no­ma, with Ph1b da­ta pre­sent­ed at AACR 2020. XCUR-FXN in pre­clin­i­cal de­vel­op­ment for pa­tients with Frie­dreich's Ataxia, us­ing ge­net­i­cal­ly tar­get­ed SNA ther­a­pies to re­move FXN tran­scrip­tion block­age. [more in­for­ma­tion]

Cell ther­a­py com­pany with 3 clin­i­cal pro­grams 1) OpRe­gen, an RPE tran­s­plant ther­a­py in Ph1/2a de­vel­op­ment for the treat­ment of dry-AMD. 2) OPC1, an oli­go­den­dro­cyte pro­gen­i­tor cell ther­a­py for acute spi­nal cord in­juries with Or­phan and RMAT desig­na­tions. 3) VAC2, an al­lo­gene­ic can­cer im­munother­a­py of anti­gen-pre­sent­ing den­drit­ic cells cur­rent­ly in a Ph 1 for NS­CLC con­duct­ed by CRUK. [more in­for­ma­tion]

Com­mer­cial­iz­ing brand­ed gener­ic top­i­cal drug prod­ucts (skin dis­eas­es). Two pos­i­tive Phase 3 pro­grams, both with PD­U­FA dates in 2021: Ep­so­lay has po­ten­tial to be first FDA-ap­proved sin­gle-agent ben­zoyl per­oxide pre­scrip­tion drug prod­uct for rosacea (PD­U­FA date on April 26th). Twy­neo has po­ten­tial to be the first acne treat­ment that con­tains fixed dose com­bi­na­tion of BPO and treti­noin (PD­U­FA date on Au­gust 1st). [more in­for­ma­tion]

Dis­cov­er­ing and de­vel­op­ing small molecule ther­a­peu­tics tar­get­ing fun­da­men­tal bi­o­log­i­cal path­ways of can­cers. Broad pipe­line of po­ten­tial­ly best-in-class on­col­o­gy can­di­dates, in­clud­ing ZN-c5, an oral se­lec­tive es­tro­gen re­cep­tor de­grad­er for ER+/HER2- breast can­cer, ZN-c3, a WEE1 in­hibi­tor, ZN-d5, a BCL-2 in­hibi­tor and ZN-e4, an EGFR in­hibi­tor. [more in­for­ma­tion]